Well if you are considering it you might have to wait a year or two for clinical trial results and commercial approval. Most likely it will result in a partnership deal with an established player like Edwards.
But from a technical point of view, it ticks an awful lot of boxes. If the trial results bear this out it's probably going to be irresistible to someone.
- Forums
- ASX - By Stock
- AVR
- Anteris Channel 9 Interview 2022
AVR
anteris technologies global corp.
Add to My Watchlist
6.60%
!
$6.30

Anteris Channel 9 Interview 2022, page-30
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$6.30 |
Change
0.390(6.60%) |
Mkt cap ! $97.48M |
Open | High | Low | Value | Volume |
$5.93 | $6.30 | $5.91 | $98.54K | 15.86K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2062 | $6.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.30 | 463 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 6.170 |
2 | 1447 | 6.150 |
1 | 3500 | 6.120 |
1 | 2000 | 6.100 |
1 | 1000 | 6.000 |
Price($) | Vol. | No. |
---|---|---|
6.230 | 159 | 1 |
6.280 | 1010 | 1 |
6.290 | 1424 | 1 |
6.300 | 1000 | 1 |
6.360 | 10 | 1 |
Last trade - 14.19pm 27/06/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online